Earlier this year, Denali Therapeutics completed a US$200,000,000 secondary offering of common shares and pre-funded warrants while engaging with the FDA on a potential priority review voucher tied to...
Source LinkEarlier this year, Denali Therapeutics completed a US$200,000,000 secondary offering of common shares and pre-funded warrants while engaging with the FDA on a potential priority review voucher tied to...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.